Illumina, Inc.
ILMN
Rang in Aktien
#614
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Aktienkurs
$262.37
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$39.62B
Veränderung (1 Tag)
-0.07%
Veränderung (1 Jahr)
163.68%
Land
US
Handel Illumina, Inc. (ILMN)
Kategorie
Healthcare
Gewinn für Illumina, Inc. (ILMN)
Gewinn im Jun 2026 TTM: $1.02B
Laut den aktuellen Finanzberichten von Illumina, Inc. betragen die aktuellen Gewinne des Unternehmens $1.02B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $-1.18B, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $-1.12B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Illumina, Inc. von 2000 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $1.02B | -6.54% |
| 2025 | $1.09B | -192.11% |
| 2024 | $-1.18B | 5.55% |
| 2023 | $-1.12B | -226.36% |
| 2022 | $884.00M | 3.27% |
| 2021 | $856.00M | -23.43% |
| 2019 | $1.12B | 25.06% |
| 2018 | $894.00M | -14.29% |
| 2017 | $1.04B | 85.92% |
| 2016 | $561.00M | -3.77% |
| 2015 | $583.00M | 29.91% |
| 2014 | $448.76M | 181.68% |
| 2013 | $159.31M | -28.43% |
| 2012 | $222.61M | 67.32% |
| 2011 | $133.05M | -28.23% |
| 2010 | $185.38M | 62.44% |
| 2009 | $114.13M | 57.01% |
| 2008 | $72.69M | -125.17% |
| 2007 | $-288.79M | -777.58% |
| 2006 | $42.62M | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $7.61B | 649.66% |
US
|
|
| $4.76B | 369.16% |
US
|
|
| $-252.70M | -124.90% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 63.35% |
US
|
